Autoimmune associations and autoantibody screening show focused recognition in patient subgroups with generalized myasthenia gravis

Human Immunology

Volumn 74, Issue 9, 2013, Pages 1184-1193

  Klein, Reinhild ^a   Marx, Alexander ^b   Ströbel, Philipp ^b,f   Schalke, Berthold ^c   Nix, Wilfred ^d   Willcox, Nick ^e  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b University Medical Centre   (Germany)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY;

ADDISON DISEASE; ADOLESCENT; ADULT; ALOPECIA; ANKYLOSING SPONDYLITIS; ANTIBODY SCREENING; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE THYROIDITIS; CELIAC DISEASE; CHILD; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOGLOBULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MUCOCUTANEOUS CANDIDIASIS; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; MYELOOPTIC NEUROPATHY; MYOKYMIA; NEPHROTIC SYNDROME; OVARY INSUFFICIENCY; PERNICIOUS ANEMIA; PRESCHOOL CHILD; PRIORITY JOURNAL; PURE RED CELL ANEMIA; RHEUMATOID ARTHRITIS; SCHOOL CHILD; SKELETAL MUSCLE; THROMBOCYTOPENIC PURPURA; THYMOMA; URTICARIA; VITILIGO;

ACETYLCHOLINE RECEPTOR; ACHR; AIRE; ANA; ANCA; ANCA WITH A CYTOPLASMIC FLUORESCENCE PATTERN; ANCA WITH A PERINUCLEAR FLUORESCENCE PATTERN; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODIES; ANTI-NUCLEAR ANTIBODIES; APS-I; AUTO-IMMUNE REGULATOR; AUTOAB; AUTOAG; AUTOANTIBODY; AUTOANTIGEN; AUTOIMMUNE POLYENDOCRINE SYNDROME TYPE I; CANCA; CHRONIC MUCOCUTANEOUS CANDIDIASIS; CMC; DOUBLE-STRANDED DEOXYRIBONUCLEIC ACID; DSDNA; EARLY-ONSET MYASTHENIA GRAVIS; ELISA; ENZYME-LINKED IMMUNO-SORBENT ASSAY; EOMG; GAD; GASTRIC PARIETAL CELLS; GENOME-WIDE ASSOCIATION STUDY; GLUTAMIC ACID DECARBOXYLASE 65; GPC; GWAS; IDDM; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IFN; IFT; IL; IMMUNOFLUORESCENCE TEST; INSULIN-DEPENDENT DIABETES MELLITUS; INTERFERON; INTERLEUKIN; ITP; LATE-ONSET MG; LOMG; MG; MS; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NEURO-MYOTONIA; NEUROMYELITIS OPTICA; NMO; NMT; NOT SIGNIFICANT; NS; PA; PANCA; PBC; PERNICIOUS ANEMIA; PMR; POLYMYALGIA RHEUMATICA; PRIMARY BILIARY CIRRHOSIS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 22; PTPN22; RA; RHEUMATOID ARTHRITIS; SD; SLE; STANDARD DEVIATION; SYSTEMIC LUPUS ERYTHEMATOSUS; TG; THYROGLOBULIN; THYROID PEROXIDASE; TNIP1; TPO; TUMOR NECROSIS FACTOR Α-INDUCED PROTEIN 3-INTERACTING PROTEIN 1; WHO; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADRENAL CORTEX; ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; CHILD; CHILD, PRESCHOOL; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUSCLE, STRIATED; MYASTHENIA GRAVIS; ORGAN SPECIFICITY; PEDIGREE; POPULATION GROUPS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 2; THYMOMA; YOUNG ADULT;

EID: 84880928569     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2013.06.020     Document Type: Article

References (68)

1. Cooper G.S., Bynum M.L., Somers E.C. Recent insights in the epidemiology of autoimmune diseases: improved estimates and understanding of clustering of diseases. J Autoimmun 2009, 33:197-207.
2. Simpson J.A. An evaluation of thymectomy in myasthenia gravis. Brain 1958, 81:112-144.
3. Simpson J.A. Myasthenia gravis; a new hypothesis. Scott Med J 1960, 5:419-436.
4. Engel A.G., Arahata K. The membrane attack complex of complement at the endplate in myasthenia gravis. Ann N Y Acad Sci 1987, 505:326-332.
5. Vincent A., Palace J., Hilton-Jones D. Myasthenia gravis. Lancet 2001, 357:2122-2128.
6. Simpson J.A. Myasthenia gravis as an autoimmune disease: clinical aspects. Ann N Y Acad Sci 1966, 135:506-516.
7. Lindstrom J., Campbell M., Nave B., Seybold M.E., Lennon V.A., Whittingham S., et al. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates and diagnostic value. Neurology 1976, 26:1054-1059.
8. Vincent A., Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myastenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 1985, 48:1246-1252.
9. Aarli J.A. Myasthenia gravis in the elderly: is it different?. Ann N Y Acad Sci 2008, 1132:238-243.
10. Compston D.A., Vincent A., Newsom-Davis J., Batchelor J.R. Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain 1980, 103:579-601.
11. Giraud M., Vandiedonck C., Garchon H.J. Genetic factors in autoimmune myasthenia gravis. Ann N Y Acad Sci 2008, 1132:180-189.
12. Janer M., Cowland A., Picard J., Campbell D., Pontarotti P., Newsom-Davis J., et al. A susceptibility region for myasthenia gravis extending into the HLA-class I sector telomeric to HLA-C. Hum Immunol 1999, 60:909-917.
13. Giraud M., Beaurain G., Yamamoto A.M., Eymard B., Tranchant C., Gajdos P., et al. Linkage of HLA to myasthenia gravis and genetic heterogeneity depending on anti-titin antibodies. Neurology 2001, 57:1555-1560.
14. z.ast;08. Ann Neurol 2012, 72:927-935.
15. Buckley C., Douek D., Newsom-Davis J., Vincent A., Willcox N. Mature, long-lived CD4(+) and CD8(+) T cells are generated by the thymoma in myasthenia gravis. Ann Neurol 2001, 50:64-72.
16. Willcox N., Schluep M., Ritter M.A., Schuurman H.J., Newsom-Davis J., Christensson B. Myasthenic and nonmyasthenic thymoma - an expansion of a minor cortical epithelial-cell subset. Am J Pathol 1987, 127:447-460.
17. Marx A., Willcox N., Leite M.I., Chuang W.Y., Schalke B., Nix W., et al. Thymoma and paraneoplastic myasthenia gravis. Autoimmunity 2010, 43:413-427.
18. Kadota Y., Okumura M., Miyoshi S., Kitagawa-Sakakida S., Inoue M., Shiono H., et al. Altered T cell development in human thymoma is related to impairment of MHC class II transactivator expression induced by interferon-gamma (IFN-gamma). Clin Exp Immunol 2000, 121:59-68.
19. Willcox N., Leite M.I., Kadota Y., Jones M., Meager A., Subrahmanyam P., et al. Autoimmunizing mechanisms in thymoma and thymus. Ann N Y Acad Sci 2008, 1132:163-173.
20. Ströbel P., Murumagi A., Klein R., Luster M., Lahti M., Krohn K., et al. Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type I (APS-I). Am J Pathol 2007, 211:563-571.
21. Mathis D., Benoist C. Aire. Annu Rev Immunol 2009, 27:287-312.
22. Husebye E.S., Perheentupa J., Rautemaa R., Kampe O. Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I. J Intern Med 2009, 265:514-529.
23. Perheentupa J. Extensive clinical experience - Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Clin Endocrinol Metabol 2006, 91:2843-2850.
24. Kisand K., Wolff A.S.B., Podkrajsek K.T., Tserel L., Link M., Kisand K.V., et al. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Exp Med 2010, 207:299-308.
25. Puel A., Doffinger R., Natividad A., Chrabieh M., Barcenas-Morales G., Picard C., et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med 2010, 207:291-297.
26. Souadjian J.V., Enriquez P., Silverstein M.N., Pépin J.M. The spectrum of diseases associated with thymoma. Coincidence or syndrome?. Arch Intern Med 1974, 134:374-379.
27. Skeie G.O., Aarli J.A., Gilhus N.E. Titin and ryanodine receptor antibodies in myasthenia gravis. Acta Neurol Scand 2006, 113:19-23.
28. Meager A., Wadhwa M., Dilger P., Bird C., Thorpe R., Newsom-Davis J., et al. Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis. Clin Exp Immunol 2003, 132:128-136.
29. Feltkamp T.E., van den Berg-Loonen P.M., Nijenhuis L.E., Engelfriet C.P., van Rossum A.L., van Loghem J.J., et al. Myasthenia gravis, autoantibodies and HL-A antigen. Br Med J 1974, 26:131-133.
30. Scherbaum W.A., Schumm F., Maisch B., Muller C., Fateh-Moghadam A., Flüchter S.H., et al. Myasthenia gravis: overlap with 'polyendocrine' autoimmunity. Klin Woschenschr 1983, 61:509-515.
31. Burn G.L., Svensson L., Sanchez-Blanco C., Saini M., Cope A.P. Why is PTPN22 a good candidate susceptibility gene for autoimmune disease?. FEBS Lett 2011, 585:3689-3698.
32. Vrolix K., Fraussen J., Molenaar P.C., Losen M., Somers V., Stinissen P., et al. The auto-antigen repertoire in myasthenia gravis. Autoimmunity 2010, 43:380-400.
33. Klein R., Timpl R., Zanetti F.R., Plester D., Berg P.A. High antibody-levels against mouse laminin with specificity for galactosyl-(alpha-1-3)galactose in patients with inner-ear diseases. Ann Otol Rhinol Laryngol 1989, 98:537-542.
34. Lacroix-Desmazes S., Kaveri S.V., Mouthon L., Ayouba A., Malanchère E., Coutinho A., et al. Self-reactive antibodies (natural autoantibodies) in healthy individuals. J Immunol Methods 1998, 216:117-137.
35. Hapnes L., Willcox N., Oftedal B.E.V., Owe J.F., Gilhus N.E., Meager A., et al. Radioligand-binding assay reveals distinct autoantibody preferences for Type I interferons in APS I and myasthenia gravis subgroups. J Clin Immunol 2012, 32:230-237.
36. Berg P.A., Doniach D., Roitt I.M. Mitochondrial antibodies in primary biliary cirrhosis. I. Localization of the antigen to mitochondrial membranes. J Exp Med 1967, 126:277-290.
37. Scherbaum W.A., Berg P.A. Development of adrenocortical failure in non-Addisonian patients with antibodies to adrenal cortex. Clin Endocrinol 1982, 16:345-352.
38. Granito A., Muratori P., Quarneti C., Pappas G., Cicola R., Muratori L. Antinuclear antibodies as ancillary markers in primary biliary cirrhosis. Expert Rev Mol Diagn 2012, 12:65-74.
39. Klein R., Eisenburg J., Weber P., Seibold F., Berg P.A. Significance and specificity of antibodies to neutrophils detected by western blotting for the serological diagnosis of primary sclerosing cholangitis. Hepatology 1991, 14:1147-1152.
40. Weber P., Wiedmann K.-H., Klein R., Walter E., Blum H.E., Berg P.A. Induction of autoimmune phenomena in patients with chronic hepatitis B treated with gamma-interferon. J Hepatol 1994, 20:321-328.
41. Klein R., Pointner H., Zilly W., GlassnerBittner B., Breuer N., Garbe W., et al. Antimitochondrial antibody profiles in primary biliary cirrhosis distinguish at early stages between a benign and a progressive course: a prospective study on 200 patients followed for 10years. Liver 1997, 17:119-128.
42. Klein R., Zanger U.M., Berg T., Hopf U., Berg P.A. Overlapping but distinct specificities of anti-liver-kidney microsome antibodies in autoimmune hepatitis type II and hepatitis C revealed by recombinant native CYP2D6 and navel peptide epitopes. Clin Exp Immunol 1999, 118:290-297.
43. Schellekens G.A., de Jong B.A.W., van den Hoogen F.H.J., van de Putte L.B.A., van Venrooij W.J. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998, 101:273-281.
44. Leite M.I., Coutinho E., Lana-Peixoto M., Apostolos S., Waters P., Sato D., et al. Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients. Neurology 2012, 78:1601-1607.
45. Mahdi H., Fisher B.A., Källberg H., Plant D., Malmström V., Rönnelid J., et al. Specific interaction between genotype, smoking and autoimmunity to citrullinated alpha-enolase in the etiology of rheumatoid arthritis. Nat Genet 2009, 41:1319-1324.
46. Newsom-Davis J., Buckley C., Clover L., Hart I., Maddison P., Tuzum E., et al. Autoimmune disorders of neuronal potassium channels, myasthenia gravis and related disorders. Ann N Y Acad Sci 2003, 998:202-210.
47. Broadley S.A., Deans J., Sawcer S.J., Clayton D., Compston D.A. Autoimmune disease in first-degree relatives of patients with multiple sclerosis. A UK survey. Brain 2000, 123:1102-1111.
48. Fletcher A.L., Calder A., Hince M.N., Boyd R.L., Chidgey A.P. The contribution of thymic stromal abnormalities to autoimmune disease. Crit Rev Immunol 2011, 31:171-187.
49. Goronzy J.J., Weyand C.M. Immune aging and autoimmunity. Cell Mol Life Sci 2012, 69:1615-1623.
50. Stanford S.M., Mustelin T.M., Bottini N. Lymphoid tyrosine phosphatase and autoimmunity: human genetics rediscovers phosphatases. Semin Immunopathol 2010, 32:127-136.
51. Jallouli M., Saadoun D., Eymard B., Leroux G., Haroche J., Le Thi Huong D., et al. The association of systemic lupus erythematosus and myasthenia gravis: a series of 17 cases with a special focus on hydroxychloroquine use and a review of the literature. J Neurol 2012, 259:1290-1297.
52. Ramagopalan S.V., Dyment D.A., Valdar W., Herrera B.M., Criscuoli M., Yee I.M., et al. Autoimmune disease in families with multiple sclerosis: a population-based study. Lancet Neurol 2007, 6:604-610.
53. Sardu C., Cocco E., Mereu A., Massa R., Cuccu A., Marrosu M.G., et al. Population based study of 12 autoimmune diseases in Sardinia, Italy: prevalence and comorbidity. PLoS One 2012, 7:e32487.
54. Tackenberg B., Schlegel K., Happel M., Eienbroker C., Gellert K., Oertel W.H., et al. Expanded TCR V beta subsets of CD8(+) T-cells in late-onset myasthenia gravis: Novel parallels with thymoma patients. J Neuroimmunol 2009, 216:85-91.
55. Dyment D.A., Ebers G.C., Sadovnick A.D. Genetics of multiple sclerosis. Lancet Neurol 2004, 3:104-110.
56. Lincoln M.R., Montpetit A., Cader M.Z., Saarela J., Dyment D.A., Tiislar M., et al. A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. Nat Genet 2005, 37:1108-1112.
57. Romi F., Bo L., Skeie G.O., Myking A., Aarli J.A., Gilhus N.E. Titin and ryanodine receptor epitopes are expressed in cortical thymoma along with costimulatory molecules. J Neuroimmunol 2002, 128:82-89.
58. Holbro A., Jauch A., Lardinois D., Tzankov A., Dirnhofer S., Hess C. High prevalence of infections and autoimmunity in patients with thymoma. Hum Immunol 2012, 73:287-290.
59. Hall J.C., Casciola-Rosen L., Rosen A. Altered structure of autoantigens during apoptosis. Rheum Dis Clin North Am 2004, 30:455-471.
60. Bozzolo E., Bellone M., Quaroni N., Voci C., Sabbadini M.G. Thymoma associated with systemic lupus erythematosus and immunologic abnormalities. Lupus 2000, 9:151-154.
61. Kisand K., Lilic D., Casanova J.L., Peterson P., Meager A., Willcox N. Mucocutaneous candidiasis and autoimmunity against cytokines in APECED and thymoma patients: clinical and pathogenetic implications. Eur J Immunol 2011, 41:1517-1527.
62. Metzger T.C., Anderson M.S. Control of central and peripheral tolerance by Aire. Immunol Rev 2011, 241:89-103.
63. Kaveri S.V. Intravenous immunoglobulin: exploiting the potential of natural antibodies. Autoimmun Rev 2012, 11:792-794.
64. Klein R., Berg P.A. Demonstration of "Naturally occurring mitochondrial antibodies" in family members of patients with primary biliary cirrhosis. Hepatology 1988, 6:299-306.
65. Himoto T., Masaki T. Extrahepatic manifestations and autoantibodies in patients with hepatitis C virus infection. Clin Dev Immunol 2012, 10.1155/2012/871401.
66. Lleo A., Invernizzi P., Gao B., Podda M., Gershwin M.E. Definition of human autoimmunity - autoantibodies versus autoimmune disease. Autoimmun Rev 2010, 9:A259-A266.
67. Zhang L., Eisenbarth G.S. Prediction and prevention of Type 1 diabetes mellitus. J Diabetes 2011, 3:48-57.
68. Croxen R., Vincent A., Newsom-Davis J., Beeson D. Myasthenia gravis in a woman with congenital AChR deficiency due to epsilon-subunit mutations. Neurology 2002, 58:1563-1565.